GEOMETRY mono-1
GEOMETRY mono-1 showed that capmatinib shrinks two thirds of untreated lung cancers with a MET exon 14 skipping mutation and about four in ten after chemotherapy, which made MET exon 14 the seventh lung cancer driver with an approved targeted drug.
Overview
GEOMETRY mono-1 enrolled patients with advanced non-small-cell lung cancer into cohorts defined by MET exon 14 skipping or by the degree of MET amplification and by prior treatment, all receiving capmatinib 400 mg twice daily. MET exon 14 skipping, found in 3 to 4 percent of lung cancers and often in older patients and sarcomatoid tumours, had responded poorly to the multikinase inhibitor crizotinib.
Among the exon 14 cohorts the response rate was 68 percent in 28 treatment-naive patients and 41 percent in 69 previously treated patients, with median durations of response of 12.6 and 9.7 months and activity against brain metastases. Tumours with high MET amplification (gene copy number 10 or more) responded in about a third of cases; lower levels of amplification did not respond. Peripheral oedema and nausea were the main side effects.
The FDA granted accelerated approval in May 2020 and regular approval in 2022; tepotinib (VISION) followed with similar results, and the two drugs are interchangeable options.
- 68 vs 41 out of 100 had their tumour shrink with Treatment-naive compared with Previously treated; 27 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Advanced non-small-cell lung cancer with MET exon 14 skipping or MET amplification: capmatinib monotherapy in cohorts by prior treatment and MET gene copy number. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (MET); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rate, MET exon 14 skippingprimary | Treatment-naive | 28 | 68% | - | - | link |
| Previously treated | 69 | 41% |
Similar pages
not linked directly; found by shared links- TreatmentTepotinib
Shares Capmatinib, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Small-molecule kinase inhibitors.
- TreatmentCapmatinib & tepotinib
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Novartis, Small-molecule kinase inhibitors.
- TargetRON receptor (MST1R)
Shares Crizotinib, MET, Non-small-cell lung cancer.
- TrialTeliMET NSCLC-01
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
- TrialLUMINOSITY
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
- TrialA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Shares Capmatinib, Non-small-cell lung cancer.
- TrialStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Shares Capmatinib, Novartis.
- PairingAmivantamab + lazertinib (first-line EGFR NSCLC)
Shares MET amplification (bypass resistance), MET, Non-small-cell lung cancer.